



This is a repository copy of *Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIII-Fc)*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/140385/>

Version: Accepted Version

Article:

Kitchen, S. orcid.org/0000-0002-6826-8519, Jennings, I., Makris, M. orcid.org/0000-0001-7622-7939 et al. (3 more authors) (2019) Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIII-Fc). *International Journal of Laboratory Hematology*, 41 (2). pp. 176-183. ISSN 1751-5521

<https://doi.org/10.1111/ijlh.12940>

This is the peer reviewed version of the following article: Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIII-Fc), which has been published in final form at <https://doi.org/10.1111/ijlh.12940> . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



**CLOTTING AND CHROMOGENIC FACTOR VIII ASSAY
VARIABILITY IN POST INFUSION AND SPIKED SAMPLES
CONTAINING FULL LENGTH RECOMBINANT FVIII OR
RECOMBINANT FACTOR VIII Fc FUSION PROTEIN (rFVIIIIFc)**

Journal:	<i>International Journal of Laboratory Hematology</i>
Manuscript ID	IJLH-07-18-0360.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Kitchen, Steve; Royal Hallamshire Hospital, Dept Of Coagulation Jennings, Ian; UK NEQAS Blood Coagulation Makris, Mike; University of Sheffield, cardiovascular Science Kitchen, Dianne Patricia; UK NEQAS Blood Coagulat Woods, Timothy; UK NEQAS Blood Coagulation Walker, Isobel; UK NEQAS Blood Coagulation
Keywords:	Factor VIII, rFVIIIIFc, Chromogenic assay, Elocta, Eloctate

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7 **CLOTTING AND CHROMOGENIC FACTOR VIII ASSAY VARIABILITY IN POST INFUSION AND**
8 **SPIKED SAMPLES CONTAINING FULL LENGTH RECOMBINANT FVIII OR RECOMBINANT**
9 **FACTOR VIII Fc FUSION PROTEIN (rFVIII-Fc)**
10
11
12

13 S. Kitchen ^{1,2}, I Jennings ¹, M Makris ^{1,3}, DP Kitchen ¹, TAL Woods¹, ID Walker ¹
14
15

- 16
17 1. UK NEQAS Blood Coagulation, Sheffield, UK
18 2. Sheffield Haemophilia and Thrombosis Centre, Sheffield UK
19 3. Department of Cardiovascular Science, University of Sheffield, UK
20
21
22
23

24 **Address for correspondence:**

25
26 **Dr Steve Kitchen**

27 Department of Coagulation

28 Royal Hallamshire Hospital

29 Glossop Road,

30 Sheffield S10 2JF, UK

31 Tel + 44 (0)114 2712955

32 Steve.Kitchen@sth.nhs.uk
33
34

35 Word count 4100 (excluding references)
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

Variability in FVIII measurement is a recognised problem, ~~although there is limited~~ ~~are few~~ data for samples containing recombinant Factor VIII Fc fusion protein (rFVIII Fc). Many studies use samples for which factor concentrate has been spiked into FVIII deficient plasma in vitro. This approach requires validation.

Aim/Methods

Four samples were distributed in a UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) survey. One contained Advate (full length recombinant FVIII) (rFVIII) added to FVIII deficient plasma, one was from a severe Haemophilia A patient after infusion of Advate, one was prepared by addition of rFVIII Fc (marketed as Elocta/Eloctate) to FVIII deficient plasma and the fourth was collected from a severe Haemophilia A patient following rFVIII Fc (Eloctate) infusion. Fifty-three haemophilia centres (UK and Scandinavia) performed one stage FVIII assays and 27 performed chromogenic FVIII assays.

Results/Conclusions

One stage assays gave significantly lower results than chromogenic assays by 7% ($p < 0.01$) and 13% ($p < 0.001$) for post Advate and Advate spiked samples, and by 22% ($p < 0.001$) and 23% ($p < 0.001$) for post rFVIII Fc and rFVIII Fc spiked samples. The inter-laboratory variation was similar for all samples, with CVs of 12-16% (chromogenic) and 10-13% (one stage). The data indicate that either product can be safely monitored by one stage or chromogenic assay. Spiked samples behaved in a similar way to post infusion samples for both products and could be substituted for post infusion samples for use in proficiency testing exercises (ie samples were commutable).

Introduction

Replacement of FVIII in subjects with haemophilia A is currently the mainstay of successful management of haemophilia A in many countries (1.). Products containing both modified and unmodified recombinant

1
2
3
4
5
6
7 FVIII are in widespread use. It is frequently the case that laboratory monitoring is useful to ensure safe,
8 efficacious and cost effective use of factor replacement therapy based on determination of FVIII activity
9
10 in post infusion samples. The assay used for potency labelling of FVIII concentrates is important since
11 the labelled potency is used during clinical trials to establish efficacious dosing recommendations. Such
12 recommendations may only be appropriate if the assay used for monitoring gives similar results to that
13 used for potency assignment. Data on the relationship between results obtained by the different FVIII
14 assays used around the world in haemophilia centres are therefore needed for all products. In the past,
15 potency for FVIII products has been assigned using the chromogenic assay in Europe and one stage
16 assay in ~~some~~ other regions. In the new era of extended half life (EHL) products the chromogenic assay
17 is increasingly the assay of choice for potency labelling of FVIII concentrates worldwide (2).

18
19
20
21
22
23
24
25 There are many publications describing differences between one stage and chromogenic assays in post
26 infusion samples. ~~including~~ Differences ~~can be observed of~~ of up to 40 % for full length recombinant
27 products (3-7). ~~This which~~ can be abolished by use of a concentrate standard for assay calibration (8). In
28 earlier studies results of chromogenic assays have been up to 50% higher than those obtained by one
29 stage assay for some B-domain deleted (BDD) FVIII products with standard half lives (5, 7, 9-17). The
30 laboratory reagents used in the assay have an impact on these differences (7,9,15,17) and use of the
31 Refacto AF laboratory standard (RLS) for one stage assay calibration has been shown to deliver
32 agreement with chromogenic results (7,10-14). Use of the RLS for assay calibration is routine in some
33 countries (7). Guidance from SSC of ISTH has suggested that the optimal approach to post infusion
34 testing of FVIII and FIX concentrates should involve assay~~ing~~ against a product specific standard
35 composed of the same material as that used for treatment (18) but the same manuscript recognised that
36 this may be difficult to implement.

37
38
39
40
41
42
43
44
45
46 Recently a BDD recombinant FVIII covalently linked to the human IgG₁ Fc domain (rFVIII₁Fc) with
47 extended half life (19) has been developed and licensed for use in some regions. This product is labelled
48 as Eloctate in the USA and Elocta in Europe, and is potency labelled using a chromogenic assay (20) .
49
50 In a field study utilising spiked samples results of chromogenic assay were up to 26% higher than those
51 obtained by one stage methods (21). There were ~~considered to be~~ no clinically important differences
52
53

1
2
3
4
5
6
7 between results obtained using different reagent sets in the one stage or chromogenic assay. Not all
8 available reagent sets were included amongst the participating centres and it is not known whether
9 samples prepared by in vitro mixing of concentrate and FVIII deficient plasma (spiked samples) can
10 successfully replace samples collected from patients after infusion of concentrate (ie are commutable).
11 Furthermore some diagnostic companies make changes to their reagents from time to time, so regular
12 reassessment of FVIII assays for post infusion monitoring is required as part of the post marketing
13 surveillance that ensures patient safety. Proficiency testing programmes such as UK NEQAS BC are a
14 convenient way to provide such surveillance.
15
16
17
18
19
20

21 The present study involved analysis of both spiked and post infusion samples from haemophilia A
22 patients containing Advate or rFVIII Fc by haemophilia centres in the UK and Scandinavia who were
23 invited to perform their FVIII assays as they would be used in routine patient monitoring. Details of their
24 current practice in relation to FVIII assays and concentrate usage were also requested.
25
26
27
28
29
30

31 **Methods**

32 This exercise comprised 4 samples as follows

- 33 1. Severe haemophilia A patient after infusion of Advate
- 34 2. FVIII deficient plasma with Advate added in vitro
- 35 3. Severe haemophilia A patient after infusion of Elocta/Eloctate
- 36 4. FVIII deficient plasma with Elocta/Eloctate added in vitro

37
38
39
40
41
42
43 Samples 1 and 3 were collected by venepuncture 10-20 mins after infusion of concentrate from different
44 patients after obtaining signed/written informed consent as approved by local ethics/clinical governance
45 authorities. These 2 samples were collected into 0.109M citrate and centrifuged to reduce residual
46 platelet counts below $10 \times 10^9/l$ prior to further processing. Sample 3 was a kind gift from Biogen (USA).
47
48
49
50

51 Samples 2 and 4 were prepared using the same FVIII deficient plasma from a severe haemophilia A
52 patient with normal VWF content (HRF, Chapel Hill USA) with in vitro addition of Advate (sample 2) or
53
54

1
2
3
4
5
6 Elocta (sample 4). Advate was purchased in Europe (Shire, UK). Elocta was a kind gift of Sobi,
7 Stockholm, Sweden). Potencies of Advate (22) and Elocta/Eloctate (20) for all 4 samples had been
8 assigned by the product manufacturer using chromogenic assays. The labelled potency of the
9 concentrates was used to calculate how much concentrate to add to FVIII deficient plasma so that the
10 spiked samples would have similar levels of chromogenic FVIII activity to the post infusion samples, but
11 no potency was assigned to test samples in advance of distribution to participating centres.
12
13
14
15
16
17

18 All 4 samples were buffered with 0.8 g% HEPES and 1.0 g% glycine, and then lyophilised ~~prior~~ to allow
19 distribution ~~through the post~~ at room temperature. Stability of such samples is excellent (23). Samples
20 were sent to 67 centres in the UK and 7 in Scandinavia in spring 2016. Participants performed FVIII
21 assays using their routine assay method including their routine assay calibration process used when
22 monitoring post-concentrate samples containing these products. Centres who maintained both one-
23 stage and chromogenic assays were asked to perform both.
24
25
26
27

28 Participants were also asked to provide ~~information with respect to which FVIII concentrates were~~
29 ~~routinely used, and for~~ details of their FVIII assay procedure for each type of product.
30
31
32

33 **Statistical analysis.**

34 Results obtained by chromogenic or one stage assay were compared using an unpaired t test as were
35 one stage FVIII assay results obtained by the two most commonly used commercial reagent sets.
36
37
38
39

40 **Results**

41 Responses and FVIII assay results were received from a total of 58 centres.

42 **One stage FVIII assay results with different reagents**

43
44
45
46 **In total 9 different APTT reagents were used in one stage assays. Results grouped according to which**
47 **APTT reagent was used are shown in Table 1. For two of these reagents there were sufficient users for**
48 **meaningful analysis. ~~For one stage factor assay testing t-~~** There were 24 users of Synthasil APTT reagent
49 in combination with calibration plasma and FVIII deficient plasma from Werfen/Instrumentation
50 Laboratory (IL, Bedford, USA) ~~in their one stage FVIII assay testing~~. There were 17 users of Actin FS
51
52
53
54

1
2
3
4
5
6
7 APTT reagent in combination with calibration plasma and FVIII deficient plasma from Siemens (Marburg,
8 Germany). At the time of the survey both Werfen/IL and Siemens deficient plasma typically contained
9 normal or near normal levels of VWF. For the 2 samples containing Advate the difference between
10 results with these two reagent sets was approximately 12% for the spiked sample and 2% for the post
11 infusion sample. For the two samples containing rFVIII Fc differences between results with these 2
12 methods were <8%. The next most widely used APTT reagent was Cephascreen (Stago, Asnieres,
13 France). Results were between 9 and 19% higher than the overall one stage median for the 4 samples.
14
15 Since the difference was similar for the 2 types of factor VIII this difference is unlikely to be related to the
16 nature of the FVIII material in the samples but rather to some other aspect of the local assay system
17 such as calibration but with only 3 users of this method the data should be interpreted cautiously .
18
19
20
21
22
23
24
25

26 **Chromogenic FVIII Assay results with different kits.**

27
28 In total 6 different kits were used amongst the 27 centres who returned chromogenic FVIII assay results.
29 Results with each commercial kit are shown in Table 2. Kits which gave results at the upper end of the
30 observed range did so for both types of FVIII.
31
32

33 **Relationship between results obtained by one stage and chromogenic FVIII assay**

34 Results of FVIII assay by one stage or chromogenic assay are summarised in Table 3. Factor VIII assay
35 results obtained by one stage assay were significantly lower ($p < 0.001$) than those obtained by
36 chromogenic assay for the 2 samples containing rFVIII Fc. The difference was 22% for the post infusion
37 sample and 23% for the spiked sample. For the 2 samples containing Advate one stage results were 7%
38 ($p < 0.01$) and 13% ($p < 0.001$) lower than chromogenic assay results for the post infusion and spiked
39 samples respectively.
40
41
42
43
44
45

46 **Comparison of spiked samples and post infusion samples.**

47 For both Advate and rFVIII Fc there was a highly significant correlation between results obtained on the
48 sample prepared by addition of concentrate to FVIII deficient plasma (spiked sample) and the result
49 obtained on the sample collected from a patient after infusion of product (post infusion). This was the
50 case for one stage assay results and for chromogenic assay data. For the Advate samples correlation
51
52
53
54

1
2
3
4
5
6
7 coefficients were $r = 0.86$ for one stage data and $r = 0.91$ for chromogenic assay users (fig 1). For the 2
8 samples containing rFVIII Fc (fig 2) the correlations were $r = 0.82$ for one stage results and $r = 0.94$ for
9 chromogenic assay results. ~~In other words Laboratories~~ who reported results at the lower end of
10 observed ranges for spiked samples also did so for post infusion samples, and conversely labs who
11 reported at the high end also did so for both spiked and post infusion samples. This suggests that for
12 both Advate and rFVIII Fc the 2 types of material were behaving in a similar way across a range of
13 chromogenic and one stage assay kits.

18 **Concentrates in use**

19 ~~Most centres routinely used more than one brand of concentrate. Three or more concentrate brands~~
20 ~~were used in 76% centres with 36% of centres using 5 or more brands. Details of which concentrates~~
21 ~~were in use at the time of the survey (spring 2016) are shown in Table 4 for the most commonly used~~
22 ~~brands together with details of whether one stage or chromogenic FVIII assays were performed for~~
23 ~~monitoring, and whether such assays were routinely calibrated with a plasma or concentrate standard.~~
24 ~~One stage assays were used by 91% of responding centres for monitoring products containing plasma~~
25 ~~derived or full length recombinant FVIII, with chromogenic assays used in 47% of centres.~~

33 **Assay design for analysis of post infusion samples**

34 ~~One stage assays were used by 91% of responding centres for monitoring products containing plasma~~
35 ~~derived or full length recombinant FVIII, with chromogenic assays used in 47% of centres.~~

Formatted: Left

36 All chromogenic and one stage assays used for monitoring Kogenate, Helixate, Advate or Haemate P
37 were calibrated using plasma standards as were chromogenic assays used for monitoring ReFacto AF.
38 When the one stage assay was used for monitoring Refacto AF one third of centres calibrated with a
39 plasma standard and 2/3 used the RLS for calibration (Table 4).

40 Overall a fresh calibration curve was prepared ~~using between 4 and 8 different dilutions (median 7~~ with
41 each assay in 12/ 54 (22%) of the centres who provided details, ~~using between 4 and 8 different~~
42 ~~dilutions (median 7)~~. A stored calibration curve was used by 39 centres (72%) using between 3 and 9
43 dilutions (median 8). Use of both stored and fresh curves depending on circumstances occurred in 6%
44 of centres. When constructing calibration curves 8 centres (15%) selected FVIII deficient plasma as

1
2
3
4
5
6
7 diluent with the remaining 85% using assay buffer for this purpose. Twenty per cent of centres used only
8 one dilution of test sample during their FVIII assay
9

13 Discussion

14
15 .A number of concentrates containing FVIII (or Factor IX) which has been modified to extend its half life
16 are in development or in use including rFVIII-Fc fusion protein which is licensed for use in the US as
17 Eloctate and in Europe as Elocta. Clinically important differences between results of FVIII assays in the
18 presence of some EHL FVIII products have been reported (24, 25), and studies are needed for any
19 new FVIII (or IX) product so that laboratories can ensure that the results obtained by any particular assay
20 method are safe to release for patient management purposes.
21
22
23
24
25

26 One stage FVIII assays continue to be more widely used than chromogenic assays as evidenced by
27 proficiency testing data (7) , surveys of practice (26, 27) and field studies related to assays (16, 21,
28 28), although the proportion of haemophilia centres returning chromogenic FVIII assay results whilst
29 participating in UK NEQAS BC exercises increased from 20% to 47% between 2011 (7) and 2016
30 (present study). This may in part be a consequence of the WFH recommendation that haemophilia
31 centres should use both one stage and chromogenic FVIII assays during the initial investigation of
32 patients with possible haemophilia in order to diagnose those haemophilia A patients who have
33 decreased activity in one type of assay but normal activity in the other (1).
34
35
36
37
38
39
40

41 In the present study FVIII activity determined using one stage assays was 22-23% lower than results
42 obtained by chromogenic assays for the 2 samples containing rFVIII-Fc and 7-13% lower for the samples
43 containing Advate. These relationships were similar to those reported in a field study incorporating
44 spiked samples where chromogenic FVIII assay results were 26% higher than one stage in a sample
45 containing 87 IU/dl rFVIII-Fc , and 12% higher for a sample with a similar concentration of Advate (21).
46
47
48
49 Thus there was a bigger difference between clotting and chromogenic assay results for rFVIII-Fc
50 compared to Advate. The authors are not aware of the full details of assays used for assignment of
51 potency to the 2 products but we cannot exclude the possibility that differences in potency assignment
52
53
54

1
2
3
4
5
6
7 methods have contributed to the different relationships between one stage and chromogenic results
8 obtained by participating centres using a range of methods in our study.

9
10 The reasons for this are unknown.

11
12 When there is a difference between results obtained with different methods it is important to consider
13 whether the difference is clinically relevant, and if so which result is more appropriate for patient
14 management purposes. Arguably the assay used for potency assignment by the drug manufacturer is
15 effectively clinically validated during the studies used to establish efficacious dosing regimens. Any
16 laboratory assay that agrees with the assay used for potency assignment or recovers close to the target
17 based on potency should therefore be clinically safe.. Advate potency is assigned using a chromogenic
18 assay in Europe or with a one stage assay in the US (22). Advate used for both spiking and patient
19 treatment samples was purchased in Europe with potency assignment by chromogenic assay. The
20 potency of rFVIII Fc is assigned by chromogenic assay in both the US and Europe (20). To the best of
21 the authors knowledge there is currently no consensus on what magnitude of difference between results
22 obtained using different assays should be considered clinically relevant but a number of laboratory field
23 studies have taken the view that divergence of up to 25-30% from the target may be acceptable for
24 monitoring therapy (16, 21, 25,) . It seems likely that the percentage% difference that clinicians could
25 accept would depend on the level of factor VIII in the test sample since a small difference in activity at
26 very low levels translates into a large difference in percentagebig % difference- |However this which
27 may have no clinical relevance (for example 4 IU/dl is 33% higher than 3 IU/dl). The impact of using an
28 assay that underestimates activity relative to that used for potency assignment is that there is the
29 potential for costly overtreatment . An assay that under estimates relative to the labelled potency by 20%
30 could lead to an extra 20% of concentrate being infused to achieve a target concentration in the patient.
31 Use of an assay that overestimates relative to potency could lead to under treatment with associated
32 clinical risk.

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48 The present study included a questionnaire about how FVIII assays are constructed since it has been
49 reported that calibration practices and assay design can cause imprecision in assay results and
50 contribute to higher inter laboratory variation in results (29). Approximately 70% of centres used a stored
51 calibration curve and 20% used only a single dilution of test sample during their assay, despite

1
2
3
4
5
6
7 recommendations against this practice from some organisations (1, 30). The inter lab variability was
8 similar for one stage and chromogenic assay results with CVs of 10-13% and 12-16% respectively.
9
10 There is usually an inverse relationship between the FVIII level and the inter laboratory CV for both one
11 stage and chromogenic methods, ie higher CVs at lower levels (16, 21, 22). In the present study we
12 observed inter laboratory CVs for samples containing Advate (10-12%) which were similar to the figures
13 of 10-18% previously reported in several studies when FVIII activity levels were in the range 35-80-IU/dl
14 (7, 21, 28). There are fewer data related to rFVIII-Fc but the CVs of 12-16% in our study are similar to
15 the 16-19% reported for a sample with approximately 90 IU/dl Eloctate (21).
16
17
18
19
20
21
22

23 Two commercial one stage assay reagent sets were used in sufficient numbers for meaningful analysis,
24 namely Synthasil with IL calibration and deficient plasmas, and Actin FS with Siemens calibration and
25 deficient plasmas. For the sample collected after Advate infusion there was a 2% difference between
26 one stage results with these two reagent sets.. We have previously reported data from an EQA exercise
27 in 2011 which also included a sample from a (different) severe haemophilia A patient collected after
28 infusion of Advate (7). In the earlier exercise there was a 39% difference between results with Synthasil
29 calibration and reference plasmas, and the results obtained using Actin FS with Siemens calibration and
30 deficient plasmas. There are a number of possible explanations for this marked change in relationship
31 over time. The properties of the concentrate may have changed or the properties of one or more
32 components of the one stage assay methods may have changed during the intervening 5 years. ~~The
33 authors are unaware of any change to the concentrate other than use of different lot numbers for
34 treatment of the 2 patients. It is more likely that something changed in relation to one or both of the two
35 laboratory assays used for FVIII activity determination in the period between 2011 and 2016.~~The
36 analyser models used in the 2 exercises were similar but different lot numbers of reagents were used.
37
38 Werfen/ IL FVIII deficient plasma used in 2016 contained normal VWF concentrations whereas lot
39 numbers in use in 2011 did not. It seems likely that use of different lot numbers of one or both of the
40 commercial calibrants and FVIII deficient plasma could have contributed to the altered relationship
41 between the results in the 2 surveys. ~~Our data indicate that the relationship between results obtained
42 with different reagents should not be considered as a constant over time but should be reassessed at~~
43
44
45
46
47
48
49
50
51
52
53
54

~~regular intervals, for example through proficiency testing. The changing relationship also has implications for the possible use of correction factors to make mathematical adjustments to the activity measured in an assay in an attempt to deliver agreement between different methods which has been recommended in prescribing information for use of one particular modified FVIII (31). The kind of change we observed between 2011 and 2016 may be a reason why some experts have specifically recommended against use of correction factors in this way (32).~~

As for one stage assay there were a number of different reagent sets/kits in use for determination of chromogenic FVIII activity. There were too few users of chromogenic assay in both the present study and Sommer study (21) to draw robust conclusions about whether different chromogenic kits give different results.

Most recent field studies related to newly developed FVIII concentrates have been performed using mock patient samples constructed in the laboratory ~~by~~ addition/spiking of FVIII concentrate into factor VIII deficient plasma (16, 21, 22, 24). It is possible that samples prepared by spiking in vitro may behave differently to genuine ~~ex-vivo~~ ~~patient~~ samples. Indeed it is well known that some types of spiked samples behave different to ex vivo patient samples in some areas of haemostasis laboratory testing (31~~33~~) and for this reason the International Standards Organisation (ISO) requires proficiency testing/external quality assurance (EQA) organisations to use test materials that mimic patient samples as closely as possible (32~~34~~). Evidence is therefore needed to assess whether spiked samples can be substituted for post infusion samples from patients in EQA exercises. In the present study there was an excellent correlation between results obtained on spiked samples and genuine post infusion patient samples. If a laboratory obtained a result at the lower end of the observed values on the spiked sample they also obtained low results on the patient sample, and centres reporting at the high end on one also reported high on the other. This was the case for both Advate and rFVIII Fc suggesting that the 2 types of sample were behaving in a similar way in a number of assay systems. Our study data therefore support the use of spiked samples for EQA/proficiency testing exercises related to these products. Such exercises are the most convenient way to provide post marketing surveillance of laboratory assay issues.

1
2
3
4
5
6
7
8 Our study has some limitations. One limitation of our study is that only samples with FVIII in the 45-60
9 IU/dl range were included. Our conclusions could in principle be limited to the levels of FVIII included in
10 our study, so inter laboratory studies incorporating genuine post infusion samples at lower and higher
11 FVIII activity are needed.
12

13
14
15 Recent guidance from the UK HCDO ([3332](#)) states the following

16 “For EHL-FVIII, a chromogenic assay will normally give a result consistent with the labelled potency.
17

18 Using an automated chromogenic assay for post infusion FVIII estimation may be the simplest solution,
19 provided the particular chromogenic assay has been validated for use with the product in question. An
20 alternative is to use a one-stage APTT-based coagulation result that has been shown to give a
21 comparable result when measuring against a human plasma standard”.
22

23 External Quality Assessment exercises like the one reported here can contribute to this validation and
24 our data confirm and extend previous studies indicating that several chromogenic and one stage assay
25 reagent sets can be safely used for monitoring rFVIII-Fc or Advate. Since assay performance
26 characteristics may change over time we recommend regular and frequent EQA/proficiency testing for
27 post infusion monitoring using samples containing all forms of clotting factor concentrate.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Acknowledgments

We are grateful to NEQAS BC participants for performing the FVIII assays on test samples and to Biogen USA for providing the post Eloctate infusion sample and to Sobi, Sweden for providing the Elocta. No funding was sought or received from any manufacturer.

Authors Contributions

SK, IDW, MM, IJ, DPK and TALW designed the study. MM consented and recruited donors. IJ, SK and DPK analysed the data. SK drafted the manuscript. IDW, MM, IJ, DPK and TALW contributed to review and finalisation of the manuscript.

Disclosures

SK has received speaker/consultancy fees from Sobi, Novonordisk, Pfizer and Bayer. MM has provided consultancy to CSL Behring, NovoNordisk and Grifols, and is the project leader for EUHANET which receives funding from Baxter and Sobi. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

References

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llina A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A. G and Treatment Guidelines Working Group of the World Federation Of Hemophilia. Guidelines for Management of Haemophilia, Haemophilia 2013; 19; 1-47.
2. Dodt J, Hubbard AR, Wicks SJ, Gray E, Neugebauer B, Charlton E and Silvester G. Potency determination of factor VIII and factor IX for new product labelling and post-infusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21; 543-9.

- 1
2
3
4
5
6
7
8
9
10 3. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity –
11 assay discrepancies. *Haemophilia* 1998; 4: 641-5.
12
13
- 14
15 4. Lee CA , Owens GB, Giangrande P. Collins P. Hay C, Gomperts E, Schroth P. Barrowcliffe
16 T. Pharmacokinetics of recombinant factor VIII (Recombinate) using one stage clotting and
17 chromogenic factor VIII assay. *Thromb Haemost* 1999; 82; 1644-7.
18
19
- 20
21 5. Hubbard AR, Weller LJ. Bevan SA. A survey of one stage and chromogenic potencies in
22 therapeutic factor VIII concentrates *B J Haem* 2002: 117; 247-8
23
24
- 25
26 6. Jennings I, Kitchen DP, Woods TAL, Kitchen S , Walker ID. Emerging Technologies and
27 Quality Assurance: the UK NEQAS perspective. *Sem Thromb Haem* 2007 ; 33; 243-9.
28
29
- 30
31 7. Kitchen S, Jennings I , Makris M , Kitchen DP, Woods TAL , Walker ID Factor VIII assay
32 variability in post infusion samples containing full length and B-Domain deleted FVIII.
33 *Haemophilia* 2016: 22:806-12.
34
35
- 36
37 8. Hubbard AR, Bevan SA , Weller LJ. Potency estimation of recombinant FVIII: effect of assay
38 method and standard. *B J Haem* 2001: 113; 533-6.
39
40
- 41
42 9. Mikaelsson M, Oswaldson U, Sanderg H. Influence of phospholipids on the assessment of
43 factor VIII activity. *Haemophilia* 1998; 4: 646-50.
44
45
- 46
47 10. Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gingeri A, Mannucci PM. A multi-centre
48 pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using
49 different assays and standards. *J Thromb Haemost* 2003: 1; 2283-2289.
50
51
52
53
54

- 1
2
3
4
5
6
7 11. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of
8 a BDD factor VIII concentrate standard in the estimation of BDD Factor VIII:C activity in
9 hemophilic plasma using the one-stage clotting assay. *J Thromb Haemost* 2004; 2; 623-628.
- 10
11
12 12. Santoro C, Iorio A, Ferrante F, Pallotta A, Pignolomi P, Biondo F, Agnelli G, Mazzucconi
13 MG. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII
14 plasma concentration via the chromogenic and one stage assays after infusion of
15 recalibrated ReFacto (B domain deleted recombinant factor VIII). *Haemophilia* 2009 : 15;
16 779- 787.
- 17
18
19
20
21 13. Pouplard C, Caron C, Aillaud MF, Ternisien C, Desconclois C, Dubanchet A, Sobas F. the
22 use of the new ReFacto AF laboratory standard allows reliable measurement of FVIII:C
23 levels in ReFacto AF mock plasma samples by a one stage assay. *Haemophilia* 2011: 17
24 e958-62.
- 25
26
27
28
29 14. Cauchie M, Toelen J, Peerlinck K, Jacquemin M. Practical and cost-effective measurement
30 of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
31 *Haemophilia* 2013; 19: e133-8.
- 32
33
34
35 15. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-
36 domain deleted recombinant factor VIII. *Semin Haem* 2001; 38: 13-23
- 37
38
39 16. Viuff D, Barrowcliffe TW, Saugstrup T, Ezban M, Lillicrap D. International comparative field
40 study of N8 evaluating factor VIII assay performance. *Haemophilia* 2011;17: 695-702.
- 41
42
43 17. Caron C, Dautzenberg MD, Delahousse B, Droulle C, Pouzol P, Dubanchet A, Rothschild C.
44 A blinded in vitro study with ReFacto mock plasma samples: similar FVIII results between
45 chromogenic assay and a one stage assay when using a higher cephalin dilution.
46 *Haemophilia* 2002 : 8; 639-643.
- 47
48
49 18. Hubbard AR, Dodt J, Lee T, Mertens K, Seitz R, Srivastava A, Weinstein M and on behalf of
50 . Factor VIII and Factor IX Subcommittee of The Science and Standardisation Committee of
51
- 52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6
7 The International Society on Thrombosis and Haemostasis. Recommendations on the
8 potency labelling of FVIII and FIX concentrates. *J Thromb Haem* 2013; 11: 988-9.
9
- 10
11 19. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA,
12 Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF . Safety and prolonged
13 activity of recombinant factor VIII Fc Fusion protein in haemophilia A patients. *Blood*.
14 2012;119 :3031-7
15
- 16
17 20. McCue J, Kshirsagar R, Selvitelli K, Lu Q, Zhang M, Mei B, Peters R, Pierce GF, Dumont J,
18 Rasp S, Reichart H. Manufacturing process used to produce long-acting recombinant factor
19 VIII Fc fusion protein. *Biologicals* 2015: 43: 213-219.
20
- 21
22 21. Sommer JM, Moore N, MCGuffie-Valentine B, Bardan S, Buyue Y, Kamphaus GD, Konkle
23 BA, Pierce GF. Comparative field study evaluating the activity of recombinant factor VIII Fc
24 fusion protein in plasma samples at clinical haemostasis laboratories. *Haemophilia* 2014: 20;
25 294-300.
26
- 27
28 22. Turacek PL, Romeder –Finger S, Apostol C, Bauer A, Crocker-Buque, Burger DA, Schall R,
29 Gritsch H. A worldwide survey and field study in clinical haemostasis laboratories to evaluate
30 FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
31 *Haemophilia* 2016: 22 ; 957-965.
32
- 33
34 23. Jennings I, Kitchen DP, Woods TAL, Kitchen S, Preston FE, walker ID. Stability of
35 coagulation proteins in lyophilised plasma. In *J Lab Haem* 2015: 37; 495-502.
36
- 37
38 24. Gu JM, Ramsey P, Evans V, Tang L, Apeler H, Leong L, Murphy JE, Laux V, Myles T.
39 Evaluation of the activated partial thromboplastin time assay for clinical monitoring of
40 PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. *Haemophilia* 2014; 20
41 :593-600.
42
- 43
44 25. A. Hillarp, A. Bowyer, M. Ezban, P. Persson and S. Kitchen Measuring FVIII activity of
45 glycopegylated recombinant Factor VIII, N8-GP, with commercially-available one-stage
46 clotting and chromogenic assay kits: A two-center study *Haemophilia* 2017: 23: 458-465.
47
- 48
49 26. Gomez K Chitlur M Survey of Laboratory tests used in the diagnosis and evaluation of
50 haemophilia A. *Thromb Haemost.* 2013 ;109:738-43
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 27. Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and
8 management of haemophilia . Haemophilia 2015; 21: 550-7
9
- 10 28. Kitchen S, Enriquez MM, Beckmann H, Katterle Y, Bruns S, Tseneklidou-Stoeter D. BAY
11 81-8973, a Full-Length Recombinant Factor VIII: Results From an International Comparative
12 Laboratory Field Study . Haemophilia 2016 : 22: e192-9.
13
14
- 15 29. Jennings I, Kitchen DP, Woods TAL , Kitchen S , Walker ID. Emerging Technologies and
16 Quality Assurance: the UK NEQAS perspective. Sem Thromb Haem 2007 ; 33; 243-9.
17
18
- 19 30. Mackie I, Cooper PC, Lawrie A, Kitchen S, Gray E, Laffan M on behalf of British Committee
20 for Standards in Haematology. Guidelines on the laboratory aspects of assays used in
21 haemostasis and thrombosis. Int J Lab Haem 2013; 35; 1-13.
22
23
- 24 ~~31. <http://labeling.cslbehring.com/PI/US/Afstyla/EN/Afstyla-Prescribing-Information.pdf>~~
25 ~~(accessed 6th July 2018)~~
26
- 27 ~~32. Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O'Donnell J, Pasi KJ,~~
28 ~~Rangarajan S, and Thomas A. The use of enhanced half life coagulation factor concentrates~~
29 ~~in routine clinical practice: guidance from UKHCDO. Haemophilia (2016), 22, 487–498~~
30
31
- 32 ~~33-31. Kitchen S, Jennings I, Woods TAL, Preston FE. Wide variability in the Sensitivity of~~
33 ~~APTT reagents for monitoring Heparin Dosage. Journal of Clinical Pathology 1996: 49; 10-~~
34 ~~14.~~
35
36
- 37 ~~32. ISO/IEC 17043:2010. Conformity assessment – General Requirements for Proficiency~~
38 ~~Testing. International Standards Organization (ISO) 2010.~~
39
40
- 41 ~~33. Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O'Donnell J, Pasi KJ,~~
42 ~~Rangarajan S, and Thomas A. The use of enhanced half-life coagulation factor concentrates~~
43 ~~in routine clinical practice: guidance from UKHCDO. Haemophilia (2016), 22, 487–498~~
44
45
- 46 ~~34.~~

Formatted: Indent: Left: 0.8", No bullets or numbering

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review



1
2
3
4
5
6
7 Legends to Figures
8
9
10
11

12 Figure 1 : Factor VIII assay results on spiked and post infusion samples containing Advate. Solid
13 symbols and solid trend line represent chromogenic assay results. Open symbols and dashed trend line
14 represent one stage assay results
15
16

17
18 Figure 2 : Factor VIII assay results on spiked and post infusion samples containing Elocta/Eloctate.
19 Solid symbols and solid trend line represent chromogenic assay results. Open symbols and dashed
20 trend line represent one stage assay results
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Table 1. One stage FVIII assay results obtained with different APTT reagents

APTT reagent used in FVIII assay	n	Post Advate Infusion		Sample Spiked with Advate		Post rFVIII Fc Infusion		Sample Spiked with rFVIII Fc	
		Median (IU/dl)	Range (IU/dl)	Median (IU/dl)	Range (IU/dl)	Median (IU/dl)	Range (IU/dl)	Median (IU/dl)	Range (IU/dl)
Actin FS/Siemens	17	56	48-68	51	42-61	47	42-58	46	41-58
Actin FSL/Siemens	2	62	61-64	60	59-61	56	51-62	54	54-55
APTT HS/Trinity	1	48	-	40	-	40	-	36	-
Cephascreen/Stago	3	66	57-71	58	55-66	56	54-59	54	53-60
Cephen LR/Hyphen	1	58	-	55	-	57	-	55	-
CK Prest/Stago	1	64	-	58	-	58	-	54	-
Pathromptin SL /Siemens	1	56	-	47	-	51	-	43	-
PTT Auto/Stago	2	59	55-63	55	52-58	55	49-60	46	38-54
Synthasil/Werfen	24	57	48-72	57	45-69	46	39-60	42	32-53

Table 2. Factor VIII results obtained with different Chromogenic assay kits

Kit used in Chromogenic FVIII assay	n	Post Advate infusion		Spiked Advate		Post rFVIIIc infusion		Spiked rFVIIIc	
		Median (IU/dl)	Range (IU/dl)	Median (IU/dl)	Range (IU/dl)	Median (IU/dl)	Range (IU/dl)	Median (IU/dl)	Range (IU/dl)
		Biophen /Hyphen	12	61	54-67	59	55-68	61	51-66
Coamatic /Chromogenix	1	51	-	51	-	49	-	51	-
Coatest/Chromogenix	3	54	53-74	52	51-69	53	51-78	55	53-76
Electrachrome/Werfen/IL	4	55	51-61	53	48-63	55	47-57	49	44-60
Siemens	5	69	66-74	69	66-74	63	57-65	64	59-68
Technoclone	2	75	73-77	72	69-74	83	82-84	84	83-84

Table 3. Summary of FVIII assay results from all centres

	Post Advate Infusion	Sample Spiked with Advate	Post rFVIII Fc Infusion	Sample Spiked with rFVIII Fc
1 stage assays (n= 53)				
Median FVIII activity (IU/dl)	57	53	47.4	45.2
CV (%)	10	11	12	13
Range of results IU/dl)	48-72	40-69	39-62	32-60
Chromogenic assays (n= 27)				
Median FVIII activity (IU/dl)	61	61	61	59
CV (%)	12	12	15	16
Range of results (IU/dl)	51-77	48-73	47-84	44-84

Table 4. Concentrates and FVIII:C assays used in different centres

Product	n*	Assay type in routine use for monitoring each product				Material used for assay Calibration	
		One Stage assay	Chromogenic assay	Two Stage clotting assay	Both One Stage & Chromogenic assays	Plasma standard	Concentrate standard
Advate	46	37	3	1	1	30	0
Haemate P	34	28	3	1	0	30	0
Helixate	25	19	1	1	1	20	0
Kogenate FS	36	27	4	1	1	29	0
ReFacto AF	46	36	7	0	2	16***	24**


*n = number of centres

**ReFacto AF laboratory standard


*** 7 users of chromogenic assays and 9 one stage users

(Apparent numerical discrepancies are a consequence of incomplete returns)

Fig 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Peer Review